biontech pfizer - Search News

News

GSK, Pfizer and CureVac

CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.

PharmExec · 1d

GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.

Seeking Alpha on MSN · 1d

GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over mRNA vaccine patents. Read more here.

8don MSN

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Business Wire5y

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development ...

CNN4y

Pfizer-BioNTech vaccine could be ready for approval by mid ... - CNN

Pfizer and BioNTech are confident they can have a vaccine against the novel coronavirus ready for regulatory approval by the middle of October or early November, BioNTech CEO and co-founder Ugur ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results